[A16-30] Emtricitabine/tenofovir alafenamide - Benefit assessment according to §35a Social Code Book V

Last updated 30.09.2016

Project no.:
A16-30

Commission:
Commission awarded on 13.05.2016 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Immune system and infections

Note:

The current version 1.1 of the dossier assessment replaces version 1.0 published on 15 August 2016.


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

15.08.2016

Emtricitabine/tenofovir alafenamide in HIV infection: added benefit not proven

Deviation from the appropriate comparator therapy / greater harm for certain patients

Project no. Title Status
A16-58 Emtricitabine/tenofovir alafenamide (HIV) - Addendum to Commission A16-30 Commission completed

Federal Joint Committee (G-BA)

2016-11-03 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.